Bank of America maintains a Buy rating on Orexigen Therapeutics OREX and raises its price target from $7 to $9.
Bank of America comments, “OREX announced that its cardiovascular outcomes trial, the Light Study, is enrolling faster than expected, with potential full enrollment by early-2013 and interim results (87 MACE events) potentially by mid-year 2013 versus a previously anticipated late-2013. We have increased confidence in a 2014 launch for Contrave and raised our probability of approval estimate by 10 percentage points to 75%, which could be conservative as the interim results only need to rule out a doubling of MACE risk in patients receiving Contrave, a low hurdle in our view. We raised our PO from $7 to $9. Note we include no value for OREX's follow-on obesity drug Empatic, which has been idled post ph. 2, pending the outcome of VVUS' Qnexa (Empatic has similar efficacy and safety issues as Qnexa).”
Orexigen Therapeutics closed at $6.24 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in